┌──────────────────────────────────────────────────────────────┐ RECORD TYPE ......... SUBJECT FILE SUBJECT TYPE ........ ORG FILE OPENED ......... 2026-07-05 17:21 UTC APPEARANCES ......... 3 ANNOTATIONS KNOWN ALIASES ....... 2 └──────────────────────────────────────────────────────────────┘
FDA (U.S. Food and Drug Administration)
ALSO APPEARS AS
- FDA
- FDA (U.S. Food and Drug Administration)
APPEARS IN THE MARGINS OF
- Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias
Study 329 was an eight-week, placebo-controlled, double-blind randomized clinical trial of paroxetine (Paxil/Seroxat) in adolescents with depression, conducted in the late 1990s and published in 2001.…
- FDA Internal Review of Study 329 Adverse Events Pre-RIAT
Study 329 was a clinical trial conducted by SmithKline Beecham (now GlaxoSmithKline) between 1994 and 1998, investigating the efficacy and safety of paroxetine and imipramine in adolescents with major…
- Study 329's Influence on FDA/EMA Data Sharing Policies
This dossier investigates whether Study 329, a controversial clinical trial on paroxetine in adolescents, directly influenced specific regulatory guidance or policy documents issued by the FDA or EMA …